[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med; 2010 Sep 2;363(10):943-53
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
  • BACKGROUND: Primary debulking surgery before initiation of chemotherapy has been the standard of care for patients with advanced ovarian cancer.
  • METHODS: We randomly assigned patients with stage IIIC or IV epithelial ovarian carcinoma, fallopian-tube carcinoma, or primary peritoneal carcinoma to primary debulking surgery followed by platinum-based chemotherapy or to neoadjuvant platinum-based chemotherapy followed by debulking surgery (so-called interval debulking surgery).
  • RESULTS: Of the 670 patients randomly assigned to a study treatment, 632 (94.3%) were eligible and started the treatment.
  • The majority of these patients had extensive stage IIIC or IV disease at primary debulking surgery (metastatic lesions that were larger than 5 cm in diameter in 74.5% of patients and larger than 10 cm in 61.6%).
  • The hazard ratio for death (intention-to-treat analysis) in the group assigned to neoadjuvant chemotherapy followed by interval debulking, as compared with the group assigned to primary debulking surgery followed by chemotherapy, was 0.98 (90% confidence interval [CI], 0.84 to 1.13; P=0.01 for noninferiority), and the hazard ratio for progressive disease was 1.01 (90% CI, 0.89 to 1.15).
  • CONCLUSIONS: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulking surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
  • Complete resection of all macroscopic disease, whether performed as primary treatment or after neoadjuvant chemotherapy, remains the objective whenever cytoreductive surgery is performed. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00003636. )
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Intention to Treat Analysis. Middle Aged. Multivariate Analysis. Neoadjuvant Therapy. Neoplasm Staging. Proportional Hazards Models. Quality of Life. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2010 Dec 9;363(24):2370-1; author reply 2372 [21142547.001]
  • [CommentIn] N Engl J Med. 2010 Dec 9;363(24):2371; author reply 2372 [21142546.001]
  • [CommentIn] N Engl J Med. 2010 Dec 9;363(24):2371; author reply 2372 [21142545.001]
  • [CommentIn] N Engl J Med. 2010 Dec 9;363(24):2371-2; author reply 2372 [21142544.001]
  • (PMID = 20818904.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00003636
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-28; United States / NCI NIH HHS / CA / 2U10 CA11488-29; United States / NCI NIH HHS / CA / 2U10 CA11488-30; United States / NCI NIH HHS / CA / 2U10 CA11488-31; United States / NCI NIH HHS / CA / 2U10 CA11488-32; United States / NCI NIH HHS / CA / 2U10 CA11488-33; United States / NCI NIH HHS / CA / 2U10 CA11488-34; United States / NCI NIH HHS / CA / 2U10 CA11488-35; United States / NCI NIH HHS / CA / 2U10 CA11488-36
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Investigator] Angioli R; Bentley J; Berteloot P; Bessette P; Boman K; Buist M; Chan K; Chan S; Coronado Martín P; Counsell R; Cruickshank DJ; Davis J; De Greve J; De Oliveira CF; De Valk B; Dittrich C; Elit L; Favalli G; Floquet A; Gauthier P; Gerdin E; Ghatage P; Gilby E; Gleeson N; Gotlieb W; Green JA; Grimshaw R; Heywood M; Hirsch V; Hoekman K; Honkoop A; Hoskins P; Kannisto P; Kaern J; Katsaros D; Kieser K; Kristeller TV; Leblanc E; Ledermann J; Leunen K; Lotocki R; Maggino T; Marth C; Martin L; Massuger L; Miller D; Mosgaard B; Mota F; Neven P; Nooij M; Nordal R; Nordin A; Ottevanger PB; Papadopoulos A; Petru E; Plante M; Popadiuk C; Provencher D; Redman C; Roozendaal KJ; Rustin G; Sadozye AH; Sandvei R; Seoane JM; Sereni MI; Sert B; Siddiqui N; Speiser P; Tholander B; Tognon G; Trimbos B; Trudeau M; Van Baal M; Van Doorn HC; Van der Velden J; Van Eygen K; Vermorken JB; Vidart Aragon JA; Wensveen CW; Zola P; Anastosopoulou A; Bethe U; Dehaes K; Demeester A; Demonty G; De Heusch E; De Rouck M; Giurgea L; Hoctin-Boes G; Teodorovic I; Ven K; Van Luijk I; Bacon M; Eisenhauer E
  •  go-up   go-down


2. Matsuo K, Bond VK, Eno ML, Im DD, Rosenshein NB: Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer; 2009 Dec 1;125(11):2721-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
  • The objective of this study was to evaluate the role of an in vitro drug resistance assay to platinum and taxane in the management of advanced epithelial ovarian, fallopian and primary peritoneal cancer.
  • All patients with FIGO Stage IIIc and IV who received postoperative chemotherapy with platinum and taxane for more than 4 courses after the initial cytoreductive surgery between 1995 and 2008 were evaluated.
  • Patients who received neoadjuvant chemotherapy were not included.
  • An in vitro drug resistance assay (EDR Assay, Oncotech, Tustin, CA) was used to determine drug resistance for each patient's tumor tissue.
  • Level of drug resistance was described as extreme (EDR), intermediate (IDR), or low (LDR).
  • Response to chemotherapy and survival were correlated to the EDR Assay.
  • In conclusion, LDR to both platinum and taxane chemotherapy, as determined by an in vitro drug resistance assay, independently predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer, especially in those patients who undergo optimal primary cytoreduction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biological Assay / methods. Drug Resistance, Neoplasm. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / secondary. Bridged Compounds / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / mortality. Endometrial Neoplasms / secondary. Female. Humans. In Vitro Techniques. Lymphatic Metastasis. Middle Aged. Organoplatinum Compounds / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Taxoids / administration & dosage


3. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res; 2006 Sep 15;12(18):5503-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • PURPOSE: This open-label study assessed the safety and immunogenicity of two doses and two routes of the anti-idiotypic monoclonal antibody abagovomab (formerly ACA125) in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • EXPERIMENTAL DESIGN: Eligible patients from the three participating institutions were any stage at diagnosis, had relapsed, and had complete or partial response to additional chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. CA-125 Antigen / immunology. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibody Formation / drug effects. Cohort Studies. Drug Administration Routes. Female. Histocompatibility Antigens Class II / blood. Histocompatibility Antigens Class II / metabolism. Humans. Interferon-gamma / biosynthesis. Middle Aged. T-Lymphocytes / immunology. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2007 Jul 1;13(13):4026; author reply 4026-7 [17606738.001]
  • (PMID = 17000686.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA89333; United States / NCI NIH HHS / CA / P01 CA052477-13
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CA-125 Antigen; 0 / Histocompatibility Antigens Class II; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


Advertisement
4. Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK: Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol; 2010 Jan;116(1):61-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma.
  • OBJECTIVE: The objective of this study was to evaluate the clinical significance of the extent of extreme drug resistance (EDR) in in vitro drug resistance assays in advanced epithelial ovarian, fallopian, and primary peritoneal cancers.
  • METHODS: A retrospective study was conducted using the database for in vitro drug resistance assay (EDR Assay, Oncotech, Inc.) results for advanced stage ovarian cancer samples obtained at primary surgery between 1995 and 2009.
  • In vitro drug resistance assay results were evaluated for thirteen drugs according to the following two groups: platinum and taxane (primary treatment group) vs remaining agents (secondary treatment group).
  • Dual-resistance was then defined as at least one EDR in the primary and secondary treatment groups.
  • Chemotherapy response and survival outcome were correlated with assay results.
  • Dual-resistance (n=53, 20.9%) was not associated with chemotherapy response (p=0.62) or survival outcomes (PFS, p=0.52; OS, p=0.11).
  • Only one (0.4%) case exhibited complete EDR to all tested drugs, and 74 (29.4%) cases showed no EDR.
  • There was no statistical correlation between total number of drugs in the EDR range and chemotherapy response (p=0.55), progression-free survival (PFS) (p=0.18), and overall survival (OS) (p=0.87).
  • Proportion of EDR, defined as the ratio of the number of EDR drugs divided by all drugs for an individual patient, was also not related to chemotherapy response (p=0.37), PFS (p=0.13), or OS (p=0.13).
  • CONCLUSIONS: Presence of extreme drug resistance to multiple agents in the in vitro drug resistance assays was not associated with survival outcomes in advanced stage epithelial ovarian, fallopian, and primary peritoneal cancers.
  • [MeSH-major] Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Databases, Factual. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor / methods. Epithelial Cells / pathology. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):8-16 [12468336.001]
  • [Cites] Am J Obstet Gynecol. 2003 Nov;189(5):1301-7 [14634558.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] J Natl Cancer Inst. 1990 Apr 4;82(7):582-8 [2313735.001]
  • [Cites] Gynecol Oncol. 1995 Jun;57(3):294-8 [7774832.001]
  • [Cites] Cancer J Sci Am. 1998 Jan-Feb;4(1):41-5 [9467045.001]
  • [Cites] Gynecol Oncol. 1998 Sep;70(3):392-7 [9790793.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):360-8 [16000215.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):360-4 [18632143.001]
  • [Cites] Int J Cancer. 2009 Dec 1;125(11):2721-7 [19530239.001]
  • [Cites] Arch Gynecol Obstet. 2010 Feb;281(2):325-8 [19455347.001]
  • (PMID = 19840886.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS625345; NLM/ PMC4162425
  •  go-up   go-down


5. Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM: Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol; 2010 Dec;119(3):451-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
  • BACKGROUND: The purpose of this study was to determine whether adding the anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to carboplatin/paclitaxel improved pathologic complete response (pCR) at reassessment surgery in epithelial ovarian, fallopian tube, or primary peritoneal cancers (OFPC).
  • METHODS: Patients with stage III-IV OFPC initiated treatment within 12 weeks of initial cytoreductive surgery or, after histologic confirmation of diagnosis, neoadjuvantly.
  • Treatment included paclitaxel (175 mg/m²) and carboplatin (AUC 6) every 3 weeks for up to 6 cycles, plus oral erlotinib 150 mg daily.
  • The primary objective was to determine whether the pCR rate at reassessment surgery was at least 60% after optimal cytoreduction at initial surgery (< 1cm residual disease), or at least 40% after suboptimal cytoreduction (at least 1cm residual disease) using a two-stage design (alpha=0.10, beta=0.10).
  • RESULTS: The study population included 56 patients with stage III-IV OFPC.
  • Twenty-eight patients had protocol therapy after optimal cytoreduction (stratum I), 23 had protocol therapy either after suboptimal cytoreduction (stratum II), and 5 received neoadjuvant therapy prior to cytoreduction (stratum III).
  • CONCLUSIONS: Among unselected patients, erlotinib plus carboplatin-paclitaxel did not improve pCR rates compared with historical experience with carboplatin-paclitaxel alone in patients with stage III-IV OFPC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant. Disease-Free Survival. Erlotinib Hydrochloride. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / genetics. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Gene Amplification / drug effects. Genes, erbB-1 / drug effects. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Quinazolines / administration & dosage. Quinazolines / adverse effects. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] Cancer. 2008 May 15;112(10):2289-300 [18393325.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Drugs. 2004;64(21):2475-92 [15482004.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):409-22 [10458260.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1572-8 [15746062.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5235-46 [16051966.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5539-48 [16061871.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):785-92 [16174225.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1441-8 [16211241.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8637-43 [16361548.001]
  • [Cites] Expert Opin Pharmacother. 2006 Feb;7(2):177-93 [16433583.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):607-10 [16554736.001]
  • [Cites] J Mol Med (Berl). 2006 Aug;84(8):671-81 [16607561.001]
  • [Cites] Drugs. 2006;66(15):2005-14; discussion 2015-6 [17100412.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1545-52 [17442998.001]
  • [Cites] J Clin Oncol. 2007 Jul 10;25(20):2873-83 [17617518.001]
  • [Cites] Drugs. 2007;67(17):2585-607 [18034592.001]
  • [Cites] J Cell Biochem. 2008 Feb 1;103(2):556-63 [17546586.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2749-55 [18438878.001]
  • [Cites] Cancer. 2008 Dec 15;113(12):3298-306 [19006196.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1419-25 [19224846.001]
  • [Cites] Gynecol Oncol. 2009 Apr;113(1):21-7 [19162309.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • (PMID = 20837357.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000096; United States / NCI NIH HHS / CM / N01 CM017103; United States / NCI NIH HHS / CA / N01CM62204; United States / NCI NIH HHS / CM / N01 CM062204; United States / NCI NIH HHS / CM / N01-CM-62204; United States / NCRR NIH HHS / RR / M01-RR-00096
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; BG3F62OND5 / Carboplatin; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS230455; NLM/ PMC3446254
  •  go-up   go-down


6. Lan C, Li Y, Liu J: Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol; 2009 Jul;114(1):42-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
  • OBJECTIVES: Intraperitoneal (IP) chemotherapy has not been widely accepted in the treatment of ovarian cancer.
  • One of the main reasons is the lack of a convenient and safe way to deliver IP therapy.
  • The objective of this study was to investigate the feasibility of delivering IP chemotherapy via direct puncture using a peripheral venous needle, as well as evaluating the associated risk factors and complications in the primary treatment of ovarian, fallopian tube, and primary peritoneal cancer.
  • METHODS: The clinical records of all patients with stage II-IV epithelial ovarian, fallopian tube, and primary peritoneal cancer at Sun Yat-sen University Cancer Center from 01/1995 to 11/2006 were reviewed retrospectively to identify patients who had received IP therapy via direct puncture after primary cytoreduction.
  • RESULTS: We identified 194 patients, and 121 (62.4%) of them successfully completed six or more cycles of IP chemotherapy, whereas 73 (37.6%) failed.
  • Two (1%) patients ceased IP therapy directly due to IP access related complications and 35 (18.1%) discontinued IP therapy for reasons unrelated to IP access.
  • Old age might be a potential risk factor for IP therapy failure.
  • The IP therapy failure rate in patients over 60 years old was higher than that in patients under or at 60 (57.1% versus 34.3%, P=0.021).
  • Body mass index were not associated with IP therapy failure.
  • CONCLUSIONS: IP access via direct puncture using a peripheral venous needle could be an alternative and safe way to deliver IP chemotherapy in the primary treatment of ovarian cancer.
  • [MeSH-major] Fallopian Tube Neoplasms / drug therapy. Infusions, Parenteral / methods. Injections, Intraperitoneal / methods. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Punctures / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Feasibility Studies. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Failure. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398124.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM: Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol; 2010 Jan 1;28(1):154-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
  • PURPOSE New strategies are needed to improve outcomes for patients with advanced ovarian cancer.
  • PATIENTS AND METHODS An open-label, phase II clinical trial was conducted in newly diagnosed patients with stage > or = IC epithelial müllerian tumors.
  • Fifty-one patients (82%) were optimally surgically cytoreduced before treatment.
  • Forty-five women (73%) had ovarian cancer, 10 (16%) had peritoneal cancer, four (6%) had fallopian tube cancers, and three (5%) had uterine papillary serous tumors.
  • The majority of patients (90%) had stage III or IV disease.
  • Treatment was associated with two pulmonary embolisms and two GIPs, all occurring during the chemotherapy phase of treatment (364 total cycles).
  • No grade 4 toxicities were seen during maintenance bevacizumab treatment.
  • Radiographic responses were documented in 21 (75%) of 28 women with measurable disease (11 complete responses and 10 partial responses), with CA-125 responses in 76% of patients (11 complete responses, 21%; and 35 partial responses, 55%).
  • CONCLUSION The regimen of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab is feasible, safe, and worthy of future study in advanced ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917843.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Leath CA 3rd, Numnum TM, Straughn JM Jr, Rocconi RP, Huh WK, Kilgore LC, Partridge EE: Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: a retrospective university experience. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):998-1002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: a retrospective university experience.
  • The aim is to evaluate disease-free (DFS) and overall survival (OS) of patients with fallopian tube carcinoma (FTCA) treated with adjuvant chemotherapy.
  • An Institutional Review Board approved retrospective review identified 38 patients with FTCA that received adjuvant chemotherapy following primary surgery from 1975 to 2001.
  • Twenty patients (53%) had FIGO stage III/IV FTCA.
  • Adjuvant chemotherapeutic regimens consisted of melphalan in 11 patients, platinum-based chemotherapy without paclitaxel in 17 patients, and the combination of paclitaxel and platinum in 10 patients.
  • Although DFS was similar for the three chemotherapy cohorts (P= 0.19), patients receiving paclitaxel had superior OS compared to patients receiving either melphalan (P= 0.02) or platinum without paclitaxel (P= 0.04).
  • Of the twenty patients with stage III/IV disease, 55% of patients had optimal cytoreduction performed at their initial surgery.
  • [MeSH-major] Carcinoma / therapy. Fallopian Tube Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome. Universities

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367322.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH: Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol; 2008 Jul;15(7):2012-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer.
  • AIM: To compare feasibility, accuracy, and safety of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer.
  • METHODS: Outcomes of patients with stage I ovarian and fallopian tubal cancer who underwent complete surgical staging at Asan Medical Center, Korea between 2004 and 2007 were retrospectively evaluated.
  • There were no between-group differences in mean age, parity, body mass index, lymph nodes retrieved, or omentum specimen size, nor were there between-group differences in the percentage of patients who were postmenopausal, those referred for restaging, in the time interval to restaging, in those upstaged after surgery, or in those with intraoperative tumor rupture.
  • The laparoscopy group had significantly shorter operating time (221 +/- 83 min versus 275 +/- 63 min, P = 0.012), less blood loss (240 +/- 228 mL versus 568 +/- 451 mL, P = 0.005), less transfusion requirement (5.3% versus 30.3%, P = 0.033), faster return of bowel movement (1.3 +/- 0.7 days versus 3.6 +/- 1.7 days.
  • P < 0.001), and shorter postoperative hospital stay (8.9 +/- 6.1 days versus 14.5 +/- 5.6 days, P = 0.002) and time interval to adjuvant chemotherapy (12.8 +/- 4.9 days versus 17.6 +/- 8.3 days, P = 0.049).
  • After a median follow-up time of 17 months (range 1-44 months), there was no recurrence or death from disease in either group.
  • Laparoscopy was safe for early-stage ovarian and fallopian tubal cancer, although follow-up time was relatively short.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Laparoscopy. Laparotomy. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437497.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Einenkel J, Ott R, Handzel R, Braumann UD, Horn LC: Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer. Int J Gynecol Cancer; 2009 Oct;19(7):1288-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer.
  • OBJECTIVES: The aim of this study was to determine the frequency of diaphragm involvement (DI) in cases of International Federation of Gynecology and Obstetrics (FIGO) stage IIIC and IV primary epithelial ovarian, fallopian tube, or peritoneal cancer; the frequency of use of different surgical techniques in managing diaphragm implants; and the procedure-associated morbidity.
  • Patients with tumors of low malignant potential and nonepithelial histologic diagnosis and those who received neoadjuvant chemotherapy were excluded.
  • The most frequent complication is serothorax, but a generous indication for intraoperative chest tube placement is solely recommended in cases of DR.
  • CONCLUSIONS: Surgical effort in achieving an optimum cytoreduction could be evaluated more precisely with parameters of DI and diaphragm-related treatment procedures.
  • The usual quality criteria for ovarian cancer surgery, such as residual tumor state and morbidity, are more marked by subjectivity and inconsistent definitions.
  • [MeSH-major] Carcinoma / epidemiology. Diaphragm. Fallopian Tube Neoplasms / epidemiology. Muscle Neoplasms / epidemiology. Muscle Neoplasms / surgery. Ovarian Neoplasms / epidemiology. Peritoneal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19823067.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ: Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol; 2009 Aug;33(8):1125-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
  • Risk-reducing salpingo-oophorectomy (RRSO) is an effective prophylactic procedure for women with mutations in BRCA1 or BRCA2 genes, both of which confer an increased lifetime risk for ovarian, tubal, peritoneal, and breast cancer.
  • In addition to lowering this risk, RRSO also offers the opportunity to detect occult early-stage fallopian tube or ovarian carcinoma.
  • The differential diagnosis of occult tubal/ovarian cancer includes a spectrum of benign tubal and ovarian alterations and also occult metastatic breast cancer, although only rare cases of the latter have been reported in RRSO.
  • Neoadjuvant breast cancer chemotherapy may contribute to diagnostic difficulty due to treatment-induced cytologic alterations.
  • With the aim of elucidating features which may help with differential diagnosis, this study reports the incidence and pathologic features of benign ovarian alterations, benign ovarian tumors, and occult primary and metastatic malignancies in prophylactic oophorectomies from 108 women with a BRCA mutation and from 35 women with other strong risk factors for hereditary breast/ovarian carcinoma.
  • We direct particular emphasis on morphologic features of primary ovarian lesions that may mimic occult metastatic breast cancer.
  • We also evaluate histologic alterations due to neoadjuvant breast cancer chemotherapy in the ovary and fallopian tube of patients who received such treatment immediately preceding RRSO.
  • Comparison is made to ovarian metastases of breast cancer in our hospital-based population of breast cancer patients, none of whom underwent RRSO.
  • Overall, 69% of RRSO patients had a personal history of breast cancer.
  • Neoadjuvant breast cancer chemotherapy was administered in 15%.
  • Occult primary carcinoma occurred in 7 (6.5%) BRCA patients (5 in fallopian tube, 1 in fallopian tube and ovary, 1 in ovary).
  • Ovarian metastasis of breast cancer occurred in 1 (1%) BRCA patient undergoing RRSO and in up to a similar proportion (0.8%) of the hospital-based population of breast cancer patients.
  • Abundant foamy, vacuolated cytoplasm due to neoadjuvant chemotherapy exposure was notable.
  • In contrast, ovarian metastases in the non-RRSO population were all clinically detected, bilateral, large, and exhibited well-developed malignant cytologic features.
  • None of the normal cell types in the ovary or tube demonstrated any cytologic alterations in RRSO patients who received neoadjuvant chemotherapy.
  • The main morphologic mimics of metastasis with superimposed chemotherapy-induced alterations in RRSO were stromal hyperthecosis (n=8), nodular hyperthecosis (n=2), adrenal rests (n=3), hilus cell nodules (n=43), and hilus cell hyperplasia (n=4).
  • Occult primary ovarian carcinoma was reliably distinguished from ovarian metastases of breast cancer by WT-1+, p53+, mammaglobin-, GCDPF-immunoprofile.
  • These results demonstrate that evaluation of RRSO specimens requires awareness of a spectrum of ovarian lesions which may mimic occult primary or metastatic carcinoma; awareness of the masquerading effects of neoadjuvant chemotherapy; and awareness of the potential morphologic differences between occult metastatic breast cancer in RRSO and non-RRSO specimens.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Genetic Predisposition to Disease. Humans. Mutation. Neoplasms, Multiple Primary / genetics. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / prevention & control. Ovariectomy. Ovary / drug effects. Ovary / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440148.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L: Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol; 2009 Mar 20;27(9):1426-31
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
  • PURPOSE: Patients with recurrent ovarian, peritoneal, or fallopian tube cancer have limited therapeutic options.
  • Main inclusion criteria were histologically or cytologically confirmed epithelial cancer of the ovary, fallopian tube, or peritoneum (any stage, grade 2 to 3 if stage I) and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) or elevated CA-125 (> 70 U/mL) in patients without measurable disease.
  • RESULTS: Median age was 65.5 years; 76% of patients had stage IIIC or IV disease, 81% had Eastern Cooperative Oncology Group performance status of 0, and 94% had prior surgery.
  • In patients with only elevated CA-125, ORR was 82% (seven CRs and two PRs of 11 patients).
  • In patients meeting both RECIST and CA-125 criteria, the ORR was 64% (seven CRs and seven PRs of 22 patients).
  • Median time to response was 1.3 months (range, 0.5 to 4.8 months).
  • The most frequent grade 3 to 4 treatment-related toxicities were neutropenia (24%) and neuropathy (9%).
  • CONCLUSION: Nab-paclitaxel is active in this group of patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
  • [MeSH-major] Albumins / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224848.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 130-nm albumin-bound paclitaxel; 0 / Albumins; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Obermair A, Taylor KH, Janda M, Nicklin JL, Crandon AJ, Perrin L: Primary fallopian tube carcinoma: the Queensland experience. Int J Gynecol Cancer; 2001 Jan-Feb;11(1):69-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma: the Queensland experience.
  • The purpose of this study was to review the experience with fallopian tube carcinoma in Queensland and to compare it with previously published data.
  • Thirty-six patients with primary fallopian tube carcinoma treated at the Queensland Gynaecological Cancer Center from 1988 to 1999 were reviewed in a retrospective clinicopathologic study.
  • All patients had primary surgery and 31/36 received chemotherapy postoperatively.
  • Abnormal vaginal bleeding (15/36) and abdominal pain (14/36) were the most common presenting symptoms at the time of diagnosis.
  • Surgical stage I disease (P = 0.02) and the absence of residual tumor after operation (P = 0.03) were the only factors associated with improved survival.
  • Twenty of the 36 patients (55%) presented with stage I disease and survival was 62.7% at 5 years.
  • The majority of the patients with fallopian tube carcinoma present with stage I disease at diagnosis, but their survival probability is low compared with that of other early stage gynecological malignancies.
  • [MeSH-major] Carcinoma / surgery. Fallopian Tube Neoplasms / surgery
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Hemorrhage / etiology. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11285036.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Vasey P, Kaye S, Paul J, Rustin G, Wilson R, Guastalla JP, Pujade-Lauraine E, Gore M, Gabra H, Carty K, Scottish Gyn Cancer Trials Group: A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers. J Clin Oncol; 2004 Jul 15;22(14_suppl):5017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers.
  • Erlotinib (Tarceva™, a highly potent reversible HER1/EGFR tyrosine-kinase inhibitor) has exhibited additive antitumor activity in combination with platinum and taxane chemotherapy preclinically, and single agent activity in heavily pretreated patients (pts).
  • In pts with EOC, D with C has a tolerable safety profile, similar efficacy as paclitaxel with C, and is an acceptable first-line option (Vasey ASCO 2002).
  • RESULTS: 39 pts (median age 59 years; stage III/IV EOC) have been treated (median 5 cycles).
  • 1/12 pts in Cohort 1 (50mg E + DC) had a drug-related DLT (plantar-palmar erythrodysethesia [PPE]).
  • In Cohort 2, 4/12 pts on 100mg E with DC had significant skin toxicity (intolerable grade 2 or 3 rash) and 1 pt had grade 3 diarrhea despite loperamide treatment.
  • The dose of E was reduced to 75mg/d in Cohort -2, and so far only 1/12 pts has had a DLT (grade 3 diarrhea).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015481.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG, Abeler VM: Carcinoma of the fallopian tube. Cancer; 2000 Nov 15;89(10):2076-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the fallopian tube.
  • BACKGROUND: The objective of the current study was to increase insight into the biology of fallopian tube carcinoma through an analysis of possible clinical and pathologic determinants of prognosis and to formulate recommendations with regard to a more optimal therapeutic approach for patients with this rare disease.
  • METHODS: A study was performed of the pathology specimens and clinical case records from 151 patients with fallopian tube carcinoma who were treated consecutively.
  • Both univariate and multivariate analyses of possible prognostic factors were performed for the whole group and for the subgroup of 41 patients with Stage I disease.
  • The possible significance of serum CA-125 levels as a tumor marker and a marker of response to platinum-containing chemotherapy was evaluated.
  • RESULTS: In multivariate analysis, disease stage, the presence of residual tumor, and a hydrosalpinx-like appearance of the fallopian tube were of independent prognostic significance for the whole cohort.
  • For patients with Stage I disease, the depth of infiltration in the tubal wall and intraoperative tumor rupture were of independent prognostic significance.
  • In 37 evaluable, platinum-naïve patients, an overall response rate of 70% was obtained with platinum-based chemotherapy, with a median response duration of 12.5 months.
  • In view of its low efficacy and high rate of serious complications, the use of postoperative radiotherapy in the treatment of patients with fallopian tube carcinoma is no longer recommended.
  • Serum CA-125 level measurements in fallopian tube carcinoma patients have the same significance as tumor and surrogate markers of response as in ovarian carcinoma patients.
  • CONCLUSIONS: Prognostic factors in patients with early stage (Stages 0 and I) fallopian tube carcinoma seem to differ from those in patients with early stage ovarian carcinoma.
  • For patients with more advanced stage disease, due to the striking similarities in prognostic and clinical characteristics between the two diseases, the authors recommend that the treatment and follow-up strategies for patients with ovarian carcinoma be adopted in the management of patients with fallopian tube carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11066048.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


16. Brown JV 3rd, Micha JP, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH: A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer; 2010 Oct;20(7):1132-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma.
  • OBJECTIVES: The purpose of this study was to assess the toxicity, progression-free survival, and response rate of advanced stage ovarian carcinoma patients treated with a novel regimen comprising paclitaxel, carboplatin, and bevacizumab.
  • RESULTS: Twenty patients received a combined total of 102 cycles of primary induction chemotherapy (median, 6; range, 2-6) and were evaluable for toxicity assessment.
  • Moreover, one patient developed a colorectal fistula and was subsequently removed from the study.
  • CONCLUSIONS: The tolerable hematologic toxicity and reasonable response rate after paclitaxel, carboplatin, and bevacizumab suggest that this regimen has moderate activity and can be safely administered to an advanced-stage ovarian carcinoma population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Papillary / drug therapy. Cystadenocarcinoma, Serous / drug therapy. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pilot Projects. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495214.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT: Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol; 2009 Feb;112(2):394-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The primary objective was to determine the completion rate of 6 cycles of paclitaxel and carboplatin chemotherapy with no dose reductions in patients > or =70 years of age.
  • METHODS: Phase II study of intravenous (IV) carboplatin Area Under the Curve (AUC) of 5 and paclitaxel 175 mg/m(2) given to patients > or =70 years of age, had any stage Müllerian cancer, and an ECOG performance status (PS) of 0-2.
  • Six of 12 completed 6 cycles of chemotherapy with no dose reductions.
  • Three patients died on study precipitating study closure; one with refractory cancer following cycle 1, one of aspiration pneumonia after cycle 1, and one with sudden death on day 5 of cycle 6.
  • Patients undergoing upfront debulking surgery tolerated chemotherapy better compared to patients receiving neoadjuvant chemotherapy.
  • CONCLUSIONS: In this prospective trial of standard carboplatin and paclitaxel chemotherapy in a heterogeneous population of elderly patients, chemotherapy was well tolerated by patients who underwent upfront debulking surgery, had a PS of 0-1, and had few comorbidities.
  • Patients not undergoing upfront debulking surgery because of either advanced cancer or poor surgical risk had excess morbidity/mortality.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genital Neoplasms, Female / drug therapy. Mixed Tumor, Mullerian / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / surgery. Female. Humans. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Prospective Studies. Quality of Life

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058838.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA: A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol; 2008 Aug;110(2):140-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
  • OBJECTIVE: Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer.
  • RESULTS: Forty-one patients were enrolled in this study; 40 received treatment and were evaluable for toxicity, and 38 were evaluable for PFS.
  • Grade 3/4 treatment-related toxicities included febrile neutropenia (12.5%), rash (2.5%), hypersensitivity reaction (7.5%), and hypomagnesemia (12.5%).
  • CONCLUSIONS: The combination of cetuximab with paclitaxel and carboplatin is adequately tolerated as primary therapy for ovarian cancer but did not demonstrate prolongation of PFS when compared to historical data.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Carboplatin / administration & dosage. Carboplatin / adverse effects. Cetuximab. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554700.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA052477
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; PQX0D8J21J / Cetuximab
  •  go-up   go-down


19. Yu AJ, Fang SH, Gao YL: [Analysis of therapeutic result and prognostic factor in primary fallopian tube carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):789-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of therapeutic result and prognostic factor in primary fallopian tube carcinoma].
  • OBJECTIVE: To investigate the impact of treatment modality and clinicopathologic profile on prognosis in primary fallopian tube carcinoma.
  • METHODS: The data of 64 cases with primary fallopian tube carcinoma treated between January 1991 and June 2006 were analyzed.
  • However, there was no significant difference in 3-year and 5-year survival rate between the group with pelvic lymphadenectomy and the group without (84.2% vs. 69.2%, P = 0.4667; 63.1% vs. 53.8%, P = 0.459), and also between the group treated using CAP/CP regimen and the group by TP regimen for chemotherapy (81.8% vs. 80.0%, P = 0.8946; 59.1% vs. 60.0% P = 0.9582).
  • It was found that the 5-year survival was correlated with FIGO stage (III-IV vs. I - II, P = 0.0197), differentiation grade (G3 vs. G1 + G2, P = 0.003), pathologic type (other type vs. serous, P = 0.0494), lymph nodes status (positive vs. negative, P = 0.0295).
  • CONCLUSION: Surgical staging, optimal cytoreduction, differentiation grade, pathologic type, lymph node status are important factors influencing the 5-year survival in primary fallopian tube carcinoma.
  • Pelvic lymphadenectomy is necessary and feasible to perform during the procedure of surgical staging and cytoreduction.
  • CAP/CP and TP regiment are similarly effective in adjuvant chemotherapy for primary fallopian tube carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Papillary / surgery. Fallopian Tube Neoplasms / surgery. Hysterectomy / methods. Ovariectomy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Survival Rate. Taxoids / therapeutic use

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396696.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Taxoids; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol; TP protocol
  •  go-up   go-down


20. Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA, Gynecologic Oncology Group Study: A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecol Oncol; 2008 Dec;111(3):455-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
  • OBJECTIVES: To estimate the anti-tumor activity and toxicity of paclitaxel poliglumex (PPX) in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (EOC) in second or third line treatment.
  • At a planned analysis following first stage accrual, the dose was reduced to 175 mg/m(2) Cohort 2) for additional accrual to 78 patients.
  • CONCLUSION: PPX at 175 mg/m(2) every 21 days has a modest activity of limited duration when given as second or third line therapy in patients with epithelial ovarian or primary peritoneal cancer.
  • The incidence of neuropathy using this dose in recurrent ovarian cancer is higher than predicted from studies in other tumors with PPX.
  • The Gynecology Oncology Group (GOG) is currently exploring its use at 135 mg/m(2) every 28 days in a randomized trial evaluating maintenance chemotherapy in first remission.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Peritoneal Neoplasms / drug therapy. Polyglutamic Acid / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Dose-Response Relationship, Drug. Fallopian Tube Neoplasms / drug therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829087.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / paclitaxel poliglumex; 25513-46-6 / Polyglutamic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Abdulhathi MB, Al-Salam S, Kassis A, Ghazal-Aswad S: Unusual presentation of cervical cancer as advanced ovarian cancer. Arch Gynecol Obstet; 2007 Oct;276(4):387-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of cervical cancer as advanced ovarian cancer.
  • We report a case of cervical adenocarcinoma presenting primarily as advanced ovarian cancer with the primary site totally silent.
  • Initial investigations with abdominal ultrasound and computerized tomography scan suggested right ovarian dermoid cyst.
  • Right salpingo-oophorectomy was performed with the histologic diagnosis of dermoid cyst.
  • Follow-up after 5 months showed a higher level of serum CA 125 (1,594 micro/ml) and a negative cervical smear.
  • Surprisingly, the histologic features of the specimen obtained at laparotomy were consistent with a moderately differentiated cervical adenocarcinoma with metastases to corpus uterus, ovaries, left fallopian tube, omentum and pleural cavity.
  • The final stage was stage IV cervical cancer.
  • Following this, the patient was referred to medical oncologist for chemotherapy.
  • CONCLUSION: Cervical carcinoma should be suspected in any patient presented with bilateral ovarian tumors and positive ascitic fluid cytology.
  • Negative cervical smears do not exclude the possibility of primary cervical carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged


22. Wagenaar HC, Pecorelli S, Vergote I, Curran D, Wagener DJ, Kobierska A, Bolis G, Bokkel-Huinink WT, Lacave AJ, Madronal C, Forn M, de Oliveira CF, Mangioni C, Nooij MA, Goupil A, Kerbrat P, Marth CH, Tumolo S, Herben MG, Zanaboni F, Vermorken JB: Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer. Eur J Gynaecol Oncol; 2001;22(3):187-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.
  • OBJECTIVE: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease.
  • RESULTS: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial.
  • Fourteen patients had FIGO stage III, and ten had stage IV disease.
  • The median time to progression was 13 months for all patients.
  • CONCLUSION: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Europe. Female. Humans. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11501769.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Schneider C, Wight E, Perucchini D, Haller U, Fink D: Primary carcinoma of the fallopian tube. A report of 19 cases with literature review. Eur J Gynaecol Oncol; 2000;21(6):578-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of the fallopian tube. A report of 19 cases with literature review.
  • Primary carcinoma of the fallopian tube is the rarest cancer of the female genital tract with an incidence of 0.5% of all gynecologic tumors.
  • Due to similarity of the clinical presentation the staging and therapeutic management have been adapted to that of ovarian cancer.
  • We retrospectively evaluated all the 19 patients who had been diagnosed with primary carcinoma of the fallopian tube at the Department of Obstetrics and Gynecology of the University of Zurich between 1977 and 1998.
  • At the time of diagnosis the median age was 62 (46-87) years.
  • Twelve (63%) women revealed FIGO stage III-IV, whereas four (21%) and three (16%) patients were diagnosed in stage I and stage II, respectively.
  • Histology showed serous-papillary carcinoma, in ten (53%) cases.
  • The 5-year survival rate was 22% for all FIGO stages and 80% for stage I.
  • None of the patients with stage III and IV survived 5 years.
  • Ovarian cancer and primary carcinoma of the fallopian tube are similar in many aspects.
  • Both carcinomas have a similar age distribution, show an increase among nulliparous women, are often of serous papillary histology, have a poor prognosis with stage and residual tumor size as important prognostic factors, and respond initially well to platinum-based chemotherapy.
  • Nevertheless, there appears to be a difference between the two diseases: primary carcinoma of the fallopian tube is more often diagnosed in an earlier stage.
  • This many be due to lower abdominal pain resulting from tubal dilatation and to abnormal bloody-watery discharge.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Switzerland / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11214613.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 38
  •  go-up   go-down


24. Hefler LA, Rosen AC, Graf AH, Lahousen M, Klein M, Leodolter S, Reinthaller A, Kainz C, Tempfer CB: The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study. Cancer; 2000 Oct 1;89(7):1555-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study.
  • BACKGROUND: Primary fallopian tube carcinoma (PFTC) is a rare disease, and data on the serum concentration of tumor marker cancer antigen 125 (CA 125) in patients with this disease are sparse.
  • The authors assessed the clinical value of the serum concentration of CA 125 as a prognostic and monitoring marker in patients with surgically treated PFTC.
  • METHODS: In a multicenter study, the concentration of CA 125 was measured in 406 serum samples from 53 patients with PFTC.
  • RESULTS: The pretreatment median serum CA 125 level was 183 U/mL (range, 6.5-5440.0 U/mL) in patients with PFTC.
  • In a univariate Cox regression model, tumor stage and serum CA 125 level were associated significantly with shortened disease free survival (P = 0.006 and P < 0.001, respectively) and with overall survival (P = 0.03 and P = 0.
  • A multivariate Cox regression model showed that pretreatment the serum CA 125 level was a prognostic factor of disease free and overall survival, independent of tumor stage (P = 0.005 and P = 0.01, respectively).
  • The pretreatment serum CA 125 level was correlated with tumor stage (P < 0.001) but not with lymph node involvement (P = 0.8), histologic grade (P = 0.3), or patient age (P = 0.2).
  • The serum CA 125 level during chemotherapy was correlated significantly with Gynecologic Oncology Group response criteria to chemotherapy (P = 0. 001).
  • During the follow-up of patients, serum CA 125 levels reached sensitivity, specificity, positive predictive value, and negative predictive value of 92%, 90%, 67%, and 98%, respectively, for differentiating between no evidence of disease and the presence of recurrent disease.
  • In 90% of the patients, an increase of serum CA 125 level preceded the clinical or radiologic diagnosis of recurrent disease with a median lead time of 3 months (range, 0.5-7.0 months).
  • CONCLUSIONS: This is the largest study to date with respect to serum CA 125 levels in patients with PFTC.
  • The current data indicate that the pretreatment serum CA 125 level is an additional independent prognostic factor of disease free and overall survival in patients with PFTC.
  • The serum CA 125 level adequately defines the response to chemotherapy and displays good sensitivity and specificity characteristics during the follow-up of patients with PFTC.
  • [MeSH-major] Biomarkers, Tumor / analysis. CA-125 Antigen / analysis. Fallopian Tube Neoplasms / immunology

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11013371.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


25. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB: Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol; 2010 May 20;28(15):2512-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
  • PURPOSE: Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair.
  • Platinum-based chemotherapy responses correlate with HR DNA repair capacity.
  • PATIENTS AND METHODS: Patients with BRCA1/2-mutated ovarian cancer were treated with olaparib within a dose-escalation and single-stage expansion of a phase I trial.
  • CONCLUSION: Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / genetics. Phthalazines / therapeutic use. Piperazines / therapeutic use. Poly(ADP-ribose) Polymerase Inhibitors
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cohort Studies. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / enzymology. Fallopian Tube Neoplasms / genetics. Fallopian Tube Neoplasms / pathology. Female. Genes, BRCA1. Genes, BRCA2. Germ-Line Mutation. Humans. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / enzymology. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / pathology. Pharmacogenetics. Poly(ADP-ribose) Polymerases / genetics


26. Havrilesky LJ, Cragun JM, Calingaert B, Alvarez Secord A, Valea FA, Clarke-Pearson DL, Berchuck A, Soper JT: The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol; 2007 Feb;104(2):401-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.
  • OBJECTIVE: The clinical significance and optimal management of patients with stage IIIA endometrial cancer are controversial.
  • We sought to determine whether recurrence and survival of patients with stage IIIA endometrial cancer differ with surgical pathologic findings (positive peritoneal cytology versus positive adnexae or serosa) and adjuvant treatment.
  • METHODS: Retrospective single institution analysis of patients surgically staged for IIIA endometrial cancer at Duke University Medical Center from 1973 to 2002.
  • Stage IIIA patients were stratified into positive cytology alone (group IIIA1, n=37) and positive adnexae or uterine serosa (group IIIA2, n=20).
  • Comparison was made with previously reported group of 467 patients with surgical stage I/II disease.
  • RESULTS: Mean age of 57 patients with stage IIIA endometrial cancer was 63.
  • Adjuvant therapies were administered to 89% patients (74% radiotherapy, 4% chemotherapy, 19% progestins).
  • RFDSS by adjuvant therapy was: external beam radiotherapy 89% (n=10), intraperitoneal P32 84% (n=21), progestins 78% (n=9), none 75% (n=6).
  • In multivariable analysis of stage I-IIIA patients (n=517), positive cytology but not adnexal/serosal metastasis was predictive of death (HR 1.70, 95% CI 1.06-2.73) and disease recurrence (HR 1.70, 95% CI 1.07-2.71).
  • CONCLUSION: Among patients with stage IIIA endometrial cancer, metastasis to adnexae or serosa does not appear to confer worse prognosis than positive cytology alone.
  • Positive cytology is an independent predictor of prognosis among patients with stage I-IIIA endometrial cancer.
  • While optimal adjuvant therapy for these groups remains unclear, recurrence patterns suggest that systemic therapies are appropriate.
  • [MeSH-major] Adnexa Uteri / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / secondary. Ovarian Neoplasms / secondary. Peritoneal Cavity / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17014898.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Rosen AC, Ausch C, Klein M, Graf AH, Metzenbauer M, Philipp K, Reiner A: p53 expression in fallopian tube carcinomas. Cancer Lett; 2000 Aug 1;156(1):1-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 expression in fallopian tube carcinomas.
  • Sixty-three women treated for primary carcinoma of the fallopian tube (PFTC) from 1980-1995 were retrospectively analyzed to study the impact of p53 expression on survival in primary carcinoma of the fallopian tube.
  • Twenty-four (38%) patients were FIGO stage I, 11 (18%) stage II, 19 (30%) stage III and nine (14%) stage IV.
  • Adjuvant therapy consisted of either chemotherapy (n: 31; 49%) or irradiation (n: 21; 33%).
  • [MeSH-major] Fallopian Tube Neoplasms / genetics. Tumor Suppressor Protein p53 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10840153.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


28. Uyar D, Frasure HE, Markman M, von Gruenigen VE: Treatment patterns by decade of life in elderly women (&gt; or =70 years of age) with ovarian cancer. Gynecol Oncol; 2005 Sep;98(3):403-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer.
  • OBJECTIVE: Elderly patients are less likely to receive surgery and platinum-based combination chemotherapy than younger patients.
  • We evaluated multi-institutional management of ovarian cancer in the elderly.
  • METHODS: Charts of women with ovarian, primary peritoneal or fallopian tube cancer from 1/1996-6/2004, age > or =70 years were reviewed.
  • Age, stage, medical co-morbidities, surgery, chemotherapy, treatment modification, toxicity and survival were analyzed.
  • Ninety-five percent of patients received platinum-based therapy and 83% received combination platinum/paclitaxel in G1, compared to 90% and 41%, respectively, in G2 (P < 0.001).
  • Of those receiving platinum therapy, 36% in G1 and 41% in G2 required dose reductions or termination of therapy.
  • Forty percent of G1 and 50% of G2 required a delay of therapy; the majority occurring in patients receiving combination therapy.
  • Hematological toxicity increased with use of combination therapy, but not with advancing age or Charlson score.
  • CONCLUSION: The extreme elderly had a decreased likelihood of receiving surgery and combination chemotherapy despite equivalent co-morbidities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000216.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA103736
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


29. Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M: Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol; 2007 Oct 1;25(28):4466-71
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
  • PURPOSE: This study was undertaken to assess if prolonged paclitaxel administration in combination with cisplatin improves overall survival (OS) in epithelial ovarian cancer (EOC).
  • PATIENTS AND METHODS: Eligible patients with suboptimal stage III or IV EOC, fallopian tube, or primary peritoneal cancer were randomly allocated to receive six cycles of cisplatin 75 mg/m2 and either paclitaxel 135 mg/m2 during 24 hours (arm 1) or paclitaxel 120 mg/m2 during 96 hours (arm 2).
  • The results of treatment with cisplatin and paclitaxel are not significantly improved by prolonging the paclitaxel infusion from 24 to 96 hours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Infusions, Intravenous. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906207.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


30. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K, Japanese Gynecologic Oncology Group: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet; 2009 Oct 17;374(9698):1331-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
  • BACKGROUND: Paclitaxel and carboplatin given every 3 weeks is standard treatment for advanced ovarian carcinoma.
  • Attempts to improve patient survival by including other drugs have yielded disappointing results.
  • We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer.
  • METHODS: Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan.
  • FINDINGS: 631 of the 637 enrolled patients were eligible for treatment and were included in the ITT population (dose-dense regimen, n=312; conventional regimen, n=319).
  • Median progression-free survival was longer in the dose-dense treatment group (28.0 months, 95% CI 22.3-35.4) than in the conventional treatment group (17.2 months, 15.7-21.1; hazard ratio [HR] 0.71; 95% CI 0.58-0.88; p=0.0015).
  • Overall survival at 3 years was higher in the dose-dense regimen group (72.1%) than in the conventional treatment group (65.1%; HR 0.75, 0.57-0.98; p=0.03).
  • 165 patients assigned to the dose-dense regimen and 117 assigned to the conventional regimen discontinued treatment early.
  • The frequency of grade 3 and 4 anaemia was higher in the dose-dense treatment group (214 [69%]) than in the conventional treatment group (137 [44%]; p<0.0001).
  • INTERPRETATION: Dose-dense weekly paclitaxel plus carboplatin improved survival compared with the conventional regimen and represents a new treatment option in women with advanced epithelial ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / drug therapy


31. Hsu Y, Sood AK, Sorosky JI: Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol; 2004 Feb;27(1):14-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
  • All patients with primary ovarian, fallopian tube, or peritoneal malignancies treated with docetaxel and platinum at the University of Iowa between January 1996 and June 1999 were identified.
  • Controls, treated with paclitaxel and platinum, were matched for age, date of diagnosis, type of cancer, stage, and residual disease.
  • Nine (45%) had grade III or IV neutropenia and fever developed in two of these patients.
  • Grade III or IV thrombocytopenia developed in two patients.
  • In contrast, among the paclitaxel/carboplatin group, grade III or IV neutropenia developed in only three patients (p < 0.05) and grade III or IV thrombocytopenia developed in two patients.
  • In the paclitaxel/carboplatin group, 13 patients developed neuropathy compared to only 2 patients (10%) in the docetaxel/carboplatin group (p < 0.05).
  • There was no difference in the clinical response between the two treatment groups.
  • The therapeutic efficacy was equivalent between the two groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage. Taxoids / administration & dosage
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Case-Control Studies. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neutropenia / chemically induced. Peripheral Nervous System Diseases / chemically induced. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14758127.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement